about
Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptorsInnate lymphoid cells in graft-versus-host diseaseE-type prostanoid receptor 4 (EP4) in disease and therapyPGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.A biased non-Gαi OXE-R antagonist demonstrates that Gαi protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE.Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo.Double-stranded RNA attenuates the barrier function of human pulmonary artery endothelial cells.Aging affects high-density lipoprotein composition and function.EP4 receptor stimulation down-regulates human eosinophil function.Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis.Cyanate is a novel inducer of endothelial icam-1 expression.Activation of EP4 receptors prevents endotoxin-induced neutrophil infiltration into the airways and enhances microvascular barrier function.Post-transcriptional down regulation of ICAM-1 in feto-placental endothelium in GDM.Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung.CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases.A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer.The heterogeneity of human CD127(+) innate lymphoid cells revealed by single-cell RNA sequencing.Inhibition of autophagy rescues palmitic acid-induced necroptosis of endothelial cells.The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein.Endothelium-derived prostaglandin I(2) controls the migration of eosinophils.Erratum to: Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis.Endothelial prostaglandin I2 restrains eosinophil trafficking.Differential response of arterial and venous endothelial cells to extracellular matrix is modulated by oxygen.Protein kinase C-ζ is involved in the inhibition of eosinophil migration.Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors.Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking.Targeting glycosaminoglycans in the lung by an engineered CXCL8 as a novel therapeutic approach to lung inflammation.Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques.Designing a mutant CCL2-HSA chimera with high glycosaminoglycan-binding affinity and selectivityAdhesion of Eosinophils to Endothelial Cells or Substrates Under Flow ConditionsLaropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formationInhibitory effect of prostaglandin I2 on bone marrow kinetics of eosinophils in the guinea pigPhotohardening restores the impaired neutrophil responsiveness to chemoattractants leukotriene B4 and formyl-methionyl-leucyl-phenylalanin in patients with polymorphic light eruptionThe pulmonary microvascular endothelial barrier function is controlled by the PGE2-EP4 signaling axisInhibitory effects of prostaglandin EP4 receptors on human eosinophilsThe role of PGE2 EP4 receptors in the regulation of endothelial barrier function.The role of prostacyclin in the interaction of endothelial cells and eosinophil granulocytes
P50
Q24306707-9A36CA1C-418A-4F28-A00A-99F4AC0734C8Q26801315-2015AF31-239F-4C31-9B94-8DCD872CB67AQ26851156-BBC8F296-3EC3-43F7-8F99-845EE7672F02Q28731227-CD114081-2BFA-4BDC-935F-C67A54475C0BQ34368772-EC48B343-A051-4923-98E0-9B3D3C6E0DDAQ34415252-9CDAC94E-1F2C-40EB-84C3-33870FA7F95DQ34731236-A674D3E2-EEDC-4797-AB6E-D44E432B80AFQ34765604-ED71BAA5-DC21-4E99-B268-70C2184A999CQ34781392-76611A26-7AF2-40FD-A6E5-A2D679AD9368Q35332774-71B8B3FF-7864-4C69-821D-0051F2439B2FQ35544507-DBF72779-0316-45B8-96BB-ED0DECCB5CAAQ35567375-4DCF5439-B949-4AFE-900E-753B6843F088Q36036213-974F88D7-D176-459D-A4F5-E30F29065D0AQ36857992-066F9D02-EFD5-49DA-99B4-34BE966EBB95Q37112098-D6709416-5513-4EE5-A60D-97E9AADC61B4Q37766068-E3C57B33-FBF7-4AA5-A48B-7EAFBCA09AE1Q39341462-D4B64BDB-4EAC-461A-B660-AC29DEE7CAC6Q40791214-09C5BC11-AF53-4ABE-A414-A279CFDF07D7Q42202028-B7B0047E-7EF8-426B-825A-1C961EB0F507Q42821512-5A5B1E81-50E1-41D8-A281-EA2FEA8A9EFCQ42931336-D0A78804-70E2-485C-A29C-31C28438CD7FQ43163399-CF1F098F-61E8-4BFF-9EFB-EA6C8ABD72D7Q45746849-9C8EDC95-8E9B-4E59-9C8B-4B58DE30FA05Q45795653-042FAE13-3A34-42F0-8D0B-78486841EEE0Q46070127-84AB8A5D-75B5-4FBC-8FE3-439F20D349B5Q46177058-8362710D-FFAB-43B1-82D4-08A72FE7B4C8Q46266946-5F516F8F-1F81-45EA-A24E-B1EC12754ACBQ47614797-20105666-84C8-4F04-8E7C-1E84B3E25E48Q52656285-C3EF94A9-ACD4-4E06-8586-C46793501A0CQ54575821-FD0AB199-D20C-4CBE-9CA5-DBD88B22F3C8Q55173831-987B4329-275E-4A36-AE66-21A6727E3B01Q55173850-81EFAA2D-603D-4306-9542-EFC527A9AB56Q55173918-7F6F1A83-9534-4DAD-B2DB-478DF4260BAAQ55173967-2F8C69AB-1DBD-403E-B5FD-74C52F5C0983Q55173973-2E059E2A-7438-4269-AB1C-6FC49C90CB43Q55173994-A0077FBA-33B2-4FA6-9AD4-E8D235FC8D69Q55173999-90DBB4B4-1843-4535-AB20-8AE59FBBCA03Q55490924-63F13326-B72A-495D-846F-D05AD5F88E42Q60734254-BBCD294F-8192-4296-BB74-ADAB3B378525
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Viktoria Konya
@ast
Viktoria Konya
@en
Viktoria Konya
@es
Viktoria Konya
@nl
Viktoria Konya
@sl
type
label
Viktoria Konya
@ast
Viktoria Konya
@en
Viktoria Konya
@es
Viktoria Konya
@nl
Viktoria Konya
@sl
prefLabel
Viktoria Konya
@ast
Viktoria Konya
@en
Viktoria Konya
@es
Viktoria Konya
@nl
Viktoria Konya
@sl
P106
P21
P31
P496
0000-0002-7999-9093